Filtered By:
Condition: Atrial Fibrillation
Management: Hospitals

This page shows you your search results in order of date. This is page number 4.

Order by Relevance | Date

Total 621 results found since Jan 2013.

Endovascular treatment for ischaemic stroke patients with and without atrial fibrillation, and the effects of adjunctive pharmacotherapy: a narrative review
Expert Opin Pharmacother. 2022 Dec 21. doi: 10.1080/14656566.2022.2161362. Online ahead of print.ABSTRACTINTRODUCTION: Endovascular thrombectomy (EVT) is associated with good clinical outcomes in anterior circulation ischaemic stroke. The impact of EVT on clinical outcomes in patients with ischaemic stroke with and without atrial fibrillation, and the effect of adjunctive pharmacological therapies with EVT, remains unclear.AREAS COVERED: The goal of this narrative review aims to provide an overview of studies which have examined: 1) associations between EVT and outcomes for patients following ischaemic stroke, 2) associati...
Source: Expert Opinion on Pharmacotherapy - December 21, 2022 Category: Drugs & Pharmacology Authors: Muath Alobaida Gregory Y H Lip Deirdre A Lane Dimitrios Sagris Andrew Hill Stephanie L Harrison Source Type: research

Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

Mr. M
Dr. Migliore I step off the subway, up the elevator, and up several flights of stairs. There’s a homeless man there who always uses the last stair of the lower staircase as a tray for his food. And by tray, I mean he sets his half-eaten rice burrito directly onto the step and picks around at it while I imagine the guacamole is mixing with Hep B and C. diff and MRSA. He looks up at me, I promise myself for the 100th time I’m going to start carrying cash or Kind bars or something; I give him my best sheepish face, and emerge at street level. I walk toward my hospital and pass a gentleman who sits on a ledge next to the ...
Source: The Hospitalist - December 1, 2022 Category: Hospital Management Authors: Lisa Casinger Tags: Essay Source Type: research

Bi-atrial versus left atrial ablation for patients with rheumatic mitral valve disease and non-paroxysmal atrial fibrillation (ABLATION): rationale, design and study protocol for a multicentre randomised controlled trial
Introduction Atrial fibrillation (AF) is common in patients with rheumatic mitral valve disease (RMVD) and increase the risk of stroke and death. Bi-atrial or left atrial ablation remains controversial for treatment of AF during mitral valve surgery. The study aims to compare the efficacy and safety of bi-atrial ablation with those of left atrial ablation among patients with RMVD and persistent or long-standing persistent AF. Methods and analysis The ABLATION trial (Bi-atrial vs Left Atrial Ablation for Patients with RMVD and Non-paroxysmal AF) is a prospective, multicentre, randomised controlled study. The trial will ran...
Source: BMJ Open - November 29, 2022 Category: General Medicine Authors: Yu, C., Li, H., Wang, Y., Chen, S., Zhao, Y., Zheng, Z. Tags: Open access, Cardiovascular medicine Source Type: research

CHA2DS2-VASc score as a prognostic indicator in patients with atrial fibrillation undergoing coronary stenting
This study aimed to assess the accuracy of CHA2DS2-VASc score for predicting and grading adverse clinical outcomes in this population.METHODS: We reviewed the clinical data of all patients with previously documented nonvalvular AF who underwent coronary stenting between January 2010 and June 2015 in 12 hospitals of Beijing, China. The study population was divided into three groups: 1) Low CHA2DS2-VASc score, ≦ 2 points, 2) Intermediate score, 3-4 points, and 3) High score, ≧ 5 points. Major adverse cardiac/cerebrovascular events (MACCE) were defined as a composite of all-cause death, nonfatal myocardial infarction, rep...
Source: Turkish Journal of Medical Sciences - November 3, 2022 Category: General Medicine Authors: Jian-Yong Zheng Dong-Tao Li Yi-Gang Q ıu Yi-Xiong Huang Zheng-Ming Xu Li Zhao Yu Chen Yi Cao Yi-Da Tang Cheng-Jun Guo Zhi-Min Ma Yong-Quan Wu Yan J ıao Tian-Chang Li Source Type: research

Rivaroxaban and apixaban in patients with atrial fibrillation; a real-world data
This study aims to analyze the real-life data of patients who were prescribed rivaroxaban and apixaban and to emphasize the points that we think will make a difference compared to randomized controlled studies.METHODS: The patients who accepted to participate in the study in whom rivaroxaban (15-20 mg) and apixaban (2.5-5 mg) were started with the diagnosis of atrial fibrillation between 01 January 2018 and 31 December 2019 and whose records were fully accessed through the hospital automation system were included in the study.RESULTS: One hundred and ninety-four (48.5%) of a total of 400 patients using rivaroxaban and apix...
Source: Turkish Journal of Medical Sciences - November 3, 2022 Category: General Medicine Authors: Onur Aslan Sinan Y ıldırım Source Type: research

CHA2DS2-VASc score as a prognostic indicator in patients with atrial fibrillation undergoing coronary stenting
This study aimed to assess the accuracy of CHA2DS2-VASc score for predicting and grading adverse clinical outcomes in this population.METHODS: We reviewed the clinical data of all patients with previously documented nonvalvular AF who underwent coronary stenting between January 2010 and June 2015 in 12 hospitals of Beijing, China. The study population was divided into three groups: 1) Low CHA2DS2-VASc score, ≦ 2 points, 2) Intermediate score, 3-4 points, and 3) High score, ≧ 5 points. Major adverse cardiac/cerebrovascular events (MACCE) were defined as a composite of all-cause death, nonfatal myocardial infarction, rep...
Source: Turkish Journal of Medical Sciences - November 3, 2022 Category: General Medicine Authors: Jian-Yong Zheng Dong-Tao Li Yi-Gang Q ıu Yi-Xiong Huang Zheng-Ming Xu Li Zhao Yu Chen Yi Cao Yi-Da Tang Cheng-Jun Guo Zhi-Min Ma Yong-Quan Wu Yan J ıao Tian-Chang Li Source Type: research

Rivaroxaban and apixaban in patients with atrial fibrillation; a real-world data
This study aims to analyze the real-life data of patients who were prescribed rivaroxaban and apixaban and to emphasize the points that we think will make a difference compared to randomized controlled studies.METHODS: The patients who accepted to participate in the study in whom rivaroxaban (15-20 mg) and apixaban (2.5-5 mg) were started with the diagnosis of atrial fibrillation between 01 January 2018 and 31 December 2019 and whose records were fully accessed through the hospital automation system were included in the study.RESULTS: One hundred and ninety-four (48.5%) of a total of 400 patients using rivaroxaban and apix...
Source: Turkish Journal of Medical Sciences - November 3, 2022 Category: General Medicine Authors: Onur Aslan Sinan Y ıldırım Source Type: research

CHA2DS2-VASc score as a prognostic indicator in patients with atrial fibrillation undergoing coronary stenting
This study aimed to assess the accuracy of CHA2DS2-VASc score for predicting and grading adverse clinical outcomes in this population.METHODS: We reviewed the clinical data of all patients with previously documented nonvalvular AF who underwent coronary stenting between January 2010 and June 2015 in 12 hospitals of Beijing, China. The study population was divided into three groups: 1) Low CHA2DS2-VASc score, ≦ 2 points, 2) Intermediate score, 3-4 points, and 3) High score, ≧ 5 points. Major adverse cardiac/cerebrovascular events (MACCE) were defined as a composite of all-cause death, nonfatal myocardial infarction, rep...
Source: Turkish Journal of Medical Sciences - November 3, 2022 Category: General Medicine Authors: Jian-Yong Zheng Dong-Tao Li Yi-Gang Q ıu Yi-Xiong Huang Zheng-Ming Xu Li Zhao Yu Chen Yi Cao Yi-Da Tang Cheng-Jun Guo Zhi-Min Ma Yong-Quan Wu Yan J ıao Tian-Chang Li Source Type: research

Rivaroxaban and apixaban in patients with atrial fibrillation; a real-world data
This study aims to analyze the real-life data of patients who were prescribed rivaroxaban and apixaban and to emphasize the points that we think will make a difference compared to randomized controlled studies.METHODS: The patients who accepted to participate in the study in whom rivaroxaban (15-20 mg) and apixaban (2.5-5 mg) were started with the diagnosis of atrial fibrillation between 01 January 2018 and 31 December 2019 and whose records were fully accessed through the hospital automation system were included in the study.RESULTS: One hundred and ninety-four (48.5%) of a total of 400 patients using rivaroxaban and apix...
Source: Turkish Journal of Medical Sciences - November 3, 2022 Category: General Medicine Authors: Onur Aslan Sinan Y ıldırım Source Type: research

CHA2DS2-VASc score as a prognostic indicator in patients with atrial fibrillation undergoing coronary stenting
This study aimed to assess the accuracy of CHA2DS2-VASc score for predicting and grading adverse clinical outcomes in this population.METHODS: We reviewed the clinical data of all patients with previously documented nonvalvular AF who underwent coronary stenting between January 2010 and June 2015 in 12 hospitals of Beijing, China. The study population was divided into three groups: 1) Low CHA2DS2-VASc score, ≦ 2 points, 2) Intermediate score, 3-4 points, and 3) High score, ≧ 5 points. Major adverse cardiac/cerebrovascular events (MACCE) were defined as a composite of all-cause death, nonfatal myocardial infarction, rep...
Source: Turkish Journal of Medical Sciences - November 3, 2022 Category: General Medicine Authors: Jian-Yong Zheng Dong-Tao Li Yi-Gang Q ıu Yi-Xiong Huang Zheng-Ming Xu Li Zhao Yu Chen Yi Cao Yi-Da Tang Cheng-Jun Guo Zhi-Min Ma Yong-Quan Wu Yan J ıao Tian-Chang Li Source Type: research

Rivaroxaban and apixaban in patients with atrial fibrillation; a real-world data
This study aims to analyze the real-life data of patients who were prescribed rivaroxaban and apixaban and to emphasize the points that we think will make a difference compared to randomized controlled studies.METHODS: The patients who accepted to participate in the study in whom rivaroxaban (15-20 mg) and apixaban (2.5-5 mg) were started with the diagnosis of atrial fibrillation between 01 January 2018 and 31 December 2019 and whose records were fully accessed through the hospital automation system were included in the study.RESULTS: One hundred and ninety-four (48.5%) of a total of 400 patients using rivaroxaban and apix...
Source: Turkish Journal of Medical Sciences - November 3, 2022 Category: General Medicine Authors: Onur Aslan Sinan Y ıldırım Source Type: research

CHA2DS2-VASc score as a prognostic indicator in patients with atrial fibrillation undergoing coronary stenting
This study aimed to assess the accuracy of CHA2DS2-VASc score for predicting and grading adverse clinical outcomes in this population.METHODS: We reviewed the clinical data of all patients with previously documented nonvalvular AF who underwent coronary stenting between January 2010 and June 2015 in 12 hospitals of Beijing, China. The study population was divided into three groups: 1) Low CHA2DS2-VASc score, ≦ 2 points, 2) Intermediate score, 3-4 points, and 3) High score, ≧ 5 points. Major adverse cardiac/cerebrovascular events (MACCE) were defined as a composite of all-cause death, nonfatal myocardial infarction, rep...
Source: Turkish Journal of Medical Sciences - November 3, 2022 Category: General Medicine Authors: Jian-Yong Zheng Dong-Tao Li Yi-Gang Q ıu Yi-Xiong Huang Zheng-Ming Xu Li Zhao Yu Chen Yi Cao Yi-Da Tang Cheng-Jun Guo Zhi-Min Ma Yong-Quan Wu Yan J ıao Tian-Chang Li Source Type: research

Rivaroxaban and apixaban in patients with atrial fibrillation; a real-world data
This study aims to analyze the real-life data of patients who were prescribed rivaroxaban and apixaban and to emphasize the points that we think will make a difference compared to randomized controlled studies.METHODS: The patients who accepted to participate in the study in whom rivaroxaban (15-20 mg) and apixaban (2.5-5 mg) were started with the diagnosis of atrial fibrillation between 01 January 2018 and 31 December 2019 and whose records were fully accessed through the hospital automation system were included in the study.RESULTS: One hundred and ninety-four (48.5%) of a total of 400 patients using rivaroxaban and apix...
Source: Turkish Journal of Medical Sciences - November 3, 2022 Category: General Medicine Authors: Onur Aslan Sinan Y ıldırım Source Type: research